Phase 2b Clinical Trial of Oral Combination Therapy PrimeC Shows Slowed Progression and Reduced Complications in ALS Patients

Phase 2b trial results show PrimeC is safe and slows ALS functional decline. Learn how this oral therapy reduced the risk of complications by 64%.

By: AXL Media

Published: Mar 16, 2026, 12:16 PM EDT

Source: Information for this report was sourced from Mass General Brigham

Targeting the Multi-Systemic Pathogenesis of ALS

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative condition that systematically destroys motor neurons, leading to total muscle failure and, ultimately, death. Traditional treatments have struggled to address the complex variety of biological malfunctions that drive the disease. However, the PARADIGM study has introduced a novel approach with PrimeC, an investigational oral therapy that combines the medications celecoxib and ciprofloxacin. This dual-action treatment is specifically designed to combat the neuroinflammation, iron accumulation, and abnormal microRNA activity that characterize the ALS brain, offering a more comprehensive strategy for stabilizing the nervous system.

Functional Outcomes and the Stabilization of Vital Tasks

The results of the 18-month trial indicate that PrimeC may provide a meaningful defense against the loss of daily functions. Although the Phase 2b study focused primarily on safety, researchers observed that participants taking the therapy scored significantly higher on the ALS Functional Rating Scale Revised compared to those on a placebo. Notably, the benefits were most pronounced in tasks involving speech and swallowing—functions that are often among the first to decline and the most distressing for patients. By 18 months, those who remained on early, continuous treatment scored nearly eight points higher than their counterparts, suggesting that the therapy may help preserve quality of life for longer periods.

Biomarker Evidence of Target Engagement

The clinical benefits observed in the trial were supported by exploratory biomarker analyses, which provided evidence that the drug was reaching its biological targets. Participants assigned to the PrimeC group showed lower levels of ferritin, a protein that indicates iron storage, and reduced levels of specific microRNA molecules associated with ALS progression. According to Dr. Jeremy M. Shefner, the consistency between these biological signals and the functional clinical endpoints provides a strong scientific foundation for the drug's efficacy. While neurofilament light chain levels remained unchanged, the shifts in iron and genetic markers suggest that PrimeC is successfully interrupting the disease's underlying toxic pathways.